We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Boston Scientific (BSX - Free Report) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year increase of 1.3%. Revenues are expected to be $5.17 billion, up 2.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Net Sales- MedSurg- Worldwide' will reach $1.75 billion. The estimate indicates a year-over-year change of +1.6%.
Analysts forecast 'Net Sales- Cardiovascular- Worldwide' to reach $3.32 billion. The estimate points to a change of -0.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales- MedSurg- Endoscopy- Worldwide' will likely reach $756.70 million. The estimate indicates a year-over-year change of +1.3%.
The consensus among analysts is that 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $308.03 million. The estimate suggests a change of +5.1% year over year.
Analysts expect 'Net Sales- MedSurg- Urology- Worldwide' to come in at $667.93 million. The estimate indicates a change of -2.1% from the prior-year quarter.
The consensus estimate for 'Net Sales- Cardiovascular- Watchman- Worldwide' stands at $449.61 million. The estimate suggests a change of -12.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' should come in at $801.01 million. The estimate indicates a change of -7.4% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' will reach $545.12 million. The estimate indicates a change of -5.7% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide' at $1.19 billion. The estimate indicates a year-over-year change of +73.5%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- U.S.' of $3.22 billion. The estimate indicates a change of -2.3% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- Rest of the World' reaching $1.84 billion. The estimate indicates a year-over-year change of +3.8%.
Shares of Boston Scientific have experienced a change of +3% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), BSX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics
Wall Street analysts expect Boston Scientific (BSX - Free Report) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year increase of 1.3%. Revenues are expected to be $5.17 billion, up 2.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Net Sales- MedSurg- Worldwide' will reach $1.75 billion. The estimate indicates a year-over-year change of +1.6%.
Analysts forecast 'Net Sales- Cardiovascular- Worldwide' to reach $3.32 billion. The estimate points to a change of -0.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales- MedSurg- Endoscopy- Worldwide' will likely reach $756.70 million. The estimate indicates a year-over-year change of +1.3%.
The consensus among analysts is that 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $308.03 million. The estimate suggests a change of +5.1% year over year.
Analysts expect 'Net Sales- MedSurg- Urology- Worldwide' to come in at $667.93 million. The estimate indicates a change of -2.1% from the prior-year quarter.
The consensus estimate for 'Net Sales- Cardiovascular- Watchman- Worldwide' stands at $449.61 million. The estimate suggests a change of -12.2% year over year.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' should come in at $801.01 million. The estimate indicates a change of -7.4% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' will reach $545.12 million. The estimate indicates a change of -5.7% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide' at $1.19 billion. The estimate indicates a year-over-year change of +73.5%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- U.S.' of $3.22 billion. The estimate indicates a change of -2.3% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- Rest of the World' reaching $1.84 billion. The estimate indicates a year-over-year change of +3.8%.
View all Key Company Metrics for Boston Scientific here>>>Shares of Boston Scientific have experienced a change of +3% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), BSX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .